Raymond James Archives - Page 2 of 4

Markets

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James initiated coverage of POINT Biopharma (NASDAQ:PNT) with an “outperform” rating and price target of $10 target. The stock closed at $6.61 on Dec. 13. POINT is a precision oncology company focused on the...

December 14, 2022

Developments

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...

November 15, 2022

Markets

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...

October 31, 2022

Markets

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James resumed coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and $7 (Canadian) price target. The stock closed at $1.36 on June 8. Eupraxia’s lead clinical candidate, EP-104IAR...

June 9, 2022

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

Markets

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...

February 22, 2022

Markets

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...

November 23, 2021

Markets

Raymond James ups Alpha Cognition PT to $3.50 (Canadian)

Raymond James raised its price target for Alpha Cognition (TSXV:ACOG) to $3.50 (Canadian) from $2.50 and maintained its “outperform” rating after the FDA accepted Alpha’s IND application to proceed into a pivotal...

September 7, 2021

Developments

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James gave winning marks to Profound Medical‘s (NASDAQ:PROF; TSX:PRN) TULSA-PRO device, compared with the Focal One HIFU device from France’s EDAP TMS SA (NASDAQ:EDAP), in a head-to-head comparison study...

August 26, 2021

Markets

Raymond James ups HLS Therapeutics to OP; PT to $26 (Canadian)

Raymond James upgraded HLS Therapeutics (TSX:HLS) to “outperform” from “market perform” and raised its price target to $26 (Canadian) from $24 after Pfizer agreed to co-market HLS’s cardiovascular drug...

August 16, 2021

Tag - Raymond James

Raymond James starts POINT Biopharma at OP; PT $10

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James resumes coverage of Eupraxia at OP; PT $7 (Canadian)

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James ups Opsens to strong buy; PT $6 (Canadian)

Raymond James ups Alpha Cognition PT to $3.50 (Canadian)

Raymond James study finds superior safety and TAM with Profound Medical’s TULSA-PRO

Raymond James ups HLS Therapeutics to OP; PT to $26 (Canadian)

General

More